1️⃣ Gilead keeps paying for oncology infrastructure
Gilead agreed to buy Tubulis for $3.15B upfront plus up to $1.85B in milestones, adding a clinical-stage NaPi2b ADC and a next-generation ADC platform.
💡 Why it matters
This is not just another asset grab. Big pharma is still willing to pay hard for payload, linker and platform quality when the clinical signal is already credible.
☕ Coffee talk
If ADC is supposedly crowded, why do the good platform companies still clear at full price?
2️⃣ Regeneron chose partnership, not ownership, for radiopharma
Regeneron entered a radiopharma collaboration with Telix across four initial solid tumor programs, with a 50/50 cost and profit split and an option to expand.
💡 Why it matters
That structure says the bottleneck is not target selection alone. Manufacturing, supply chain and radiopharma execution now carry enough weight to keep a company like Regeneron from doing this alone.
☕ Coffee talk
If the antibody owner still needs a specialist partner, what is the real asset here beyond the biology?
3️⃣ Bain built a $300M autoimmunity NewCo with recycled assets and proven operators
Beeline emerged from stealth with a $300M Series A, five Bristol Myers Squibb programs and a leadership team built around the SpringWorks playbook.
💡 Why it matters
This is a cleaner venture model for this market: skip blank-sheet discovery, start with validated biology, and back operators who already know how to get from carve-out to exit.
☕ Coffee talk
Is this still venture creation, or just private equity with better science and longer timelines?